Merck & Co
Every trial this sponsor leads in the registry, and everything it has published.
229 active · 10% of this sponsor’s registry footprint
Not shown above: 20 Phase 1 healthy-volunteer trials and 2 trials whose condition matched no therapy area.
Trials by phase
Pipeline by phase · 59 drugs in active development
Phase 3 · 23 drugs
Phase 2 · 13 drugs
Phase 1 · 21 drugs
Phase 4 · 2 drugs
Not counted above: 1 combination backbone (established drugs used alongside the assets) and 1 unphased intervention.
Active trials only, code names and brands merged. 1,650 completed trials are in the counts above but their drugs are not folded into this pipeline.
Disease landscapes · 4 of 10 curated
Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.
Track your drug now for free
We check every one of its trials daily and tell you what moved.
- Status changeStatus moved to completedWas recruiting · always alerts
- Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
- New trialNew trial registered in your scopeFirst posted within 30 days
- Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
- Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English